Skip to content

Hepatocellular carcinoma — epidemiology and etiology

TL;DR — Liver cancer caused 7.8% of global cancer deaths in 2022, and HCC constitutes the great majority of primary liver cancers (Bray 2024, PMID 38572751; McGlynn 2021, PMID 32319693). The burden is geographically unequal and is moving from predominantly HBV/HCV-associated disease toward alcohol-associated and metabolic liver disease, although viral hepatitis remains globally dominant (Singal 2023, PMID 37884736). Etiology matters because it changes age and geography of presentation, the probability of cirrhosis, surveillance eligibility, competing liver mortality, and prevention strategy. HBV vaccination and viral suppression/cure can prevent HCC, but residual risk persists after treatment—especially once cirrhosis is established (Chang 2009, PMID 19759364; Lv 2024, PMID 38965190). The central prevention gap is the absence of comparably effective population-level interventions for alcohol-associated and metabolic HCC.

What is being counted

Population registries usually report liver cancer, not histologically confirmed HCC. This is a reasonable but imperfect proxy because HCC is the dominant primary liver-cancer histology; intrahepatic cholangiocarcinoma and rarer tumors remain mixed into many burden estimates (McGlynn 2021, PMID 32319693). Comparisons therefore require attention to:

  • whether the endpoint is all liver cancer or HCC;
  • incidence or mortality rather than prevalence;
  • crude or age-standardized rates;
  • registry, claims, death-certificate, or modeled data;
  • calendar period and viral-treatment era;
  • whether mixed etiologies were assigned hierarchically.

These distinctions explain why estimates from different sources should be displayed side by side rather than averaged.

Global burden

Indicator Estimate Population and method Interpretation
Global cancer cases, all sites nearly 20 million in 2022 IARC GLOBOCAN modeled estimates, 185 countries Denominator for site rankings (Bray 2024, PMID 38572751)
Global cancer deaths, all sites 9.7 million in 2022 IARC GLOBOCAN modeled estimates Cancer-mortality denominator (Bray 2024, PMID 38572751)
Liver-cancer share of cancer deaths 7.8% IARC GLOBOCAN 2022 Second only to lung and colorectal cancer in the cited ranking (Bray 2024, PMID 38572751)
HCC share of primary liver cancer great majority Histologic synthesis Registry liver-cancer estimates approximate, but do not equal, HCC burden (McGlynn 2021, PMID 32319693)
Chronic liver disease prevalence ~1.5 billion people Review of global epidemiologic sources Size of the substrate from which cirrhosis and HCC emerge (Moon 2020, PMID 31401364)
Chronic liver disease/cirrhosis incidence 20.7 per 100,000; 13% increase since 2000 Global review incorporating CDC and GBD data The at-risk pool is not static (Moon 2020, PMID 31401364)

The global label conceals sharp regional differences. HBV-associated HCC remains concentrated in areas with historically high endemic HBV prevalence; HCV shaped much of the late-twentieth-century burden in Japan, Europe, and North America; aflatoxin exposure amplifies risk in some food systems; and alcohol and metabolic disease are rising across regions (Yang 2019, PMID 31439937; McGlynn 2021, PMID 32319693).

Etiologic architecture

Etiology or exposure Causal position Prevention lever Residual problem
Chronic HBV Major global cause; HCC can occur without cirrhosis Birth-dose/universal vaccination; prevention of transmission; nucleos(t)ide therapy Risk falls but is not abolished; access and late diagnosis remain limiting (Chang 2009, PMID 19759364; Singal 2023, PMID 37884736)
Chronic HCV Major cause through progressive fibrosis/cirrhosis Harm reduction, testing, direct-acting antiviral cure Cirrhosis retains material HCC risk after sustained virologic response (Lv 2024, PMID 38965190)
Alcohol-associated liver disease Cirrhosis-mediated risk with metabolic and genetic modifiers Reduce heavy alcohol exposure; treat alcohol-use disorder Population consumption and alcohol-associated liver mortality remain difficult to reverse (Huang 2023, PMID 36258033)
MASLD/MASH Large and growing population; HCC sometimes precedes recognized cirrhosis Weight, diabetes, and cardiometabolic prevention; fibrosis detection Low individual risk but enormous denominator; no validated population HCC-screening strategy (Huang 2021, PMID 33349658)
Aflatoxin B1 Dietary toxin; interacts with HBV and leaves a characteristic mutational signature Crop storage, food monitoring, HBV control Exposure measurement and enforcement vary (McGlynn 2021, PMID 32319693)
Tobacco Modifiable co-exposure Tobacco control Often correlated with alcohol and socioeconomic exposures (Yang 2019, PMID 31439937)
Inherited/metabolic disorders Smaller population attributable fraction Disease-specific treatment and surveillance Evidence is condition-specific and often registry-limited (Yang 2019, PMID 31439937)

Etiologies commonly coexist. A patient may have cured HCV, metabolic dysfunction, alcohol exposure, and established cirrhosis simultaneously. Single-cause attribution can therefore understate interaction and depends on the hierarchy used by a registry.

The viral-to-nonviral transition

The transition is not the disappearance of viral HCC. It is a change in the relative composition of incident disease as vaccination and antiviral treatment reduce viral risk while obesity, diabetes, and harmful alcohol use expand (Singal 2023, PMID 37884736; Moon 2020, PMID 31401364).

Three mechanisms operate on different time scales:

  1. Cohort replacement after HBV vaccination. Taiwan's universal vaccination programme was followed by significantly lower HCC incidence in vaccinated birth cohorts through 20 years of follow-up (Chang 2009, PMID 19759364).
  2. Suppression or cure among already infected adults. HBV suppression and HCV cure reduce progression and HCC risk, but treatment often begins after fibrosis has accumulated (Singal 2023, PMID 37884736; Lv 2024, PMID 38965190).
  3. Growth of nonviral substrates. Metabolic syndrome, type 2 diabetes, obesity, MASLD, and alcohol-associated disease expand the pool of people at risk (McGlynn 2021, PMID 32319693; Huang 2023, PMID 36258033).

The policy implication is a long overlap period: programmes must sustain vaccination, hepatitis testing and treatment while also building metabolic and alcohol prevention rather than replacing one agenda with another.

HBV: prevention with long latency

HBV differs from most other HCC etiologies because carcinogenesis can occur in the absence of cirrhosis. Viral integration, chronic inflammation, and fibrosis contribute in proportions that vary by age at infection and viral activity (McGlynn 2021, PMID 32319693).

The Taiwanese natural experiment is the clearest population demonstration of cancer prevention through vaccination. The 20-year follow-up compared national HCC registries across vaccinated and unvaccinated birth cohorts and found lower HCC incidence among vaccinated children and young adults (Chang 2009, PMID 19759364). The result supports vaccination as cancer prevention, while failures related to incomplete dosing and maternal infection show why birth-dose delivery and prevention of perinatal transmission remain important.

Evidence for antiviral therapy is more methodologically heterogeneous. An older meta-analysis found discordant results by design—randomized trials did not establish a reduction in HCC or mortality, cohort studies paradoxically suggested higher risk, and case-control studies suggested lower risk—illustrating confounding by indication and disease severity (Thiele 2013, PMID 23945731). Modern potent antiviral practice is supported by a wider evidence base, but treated patients with advanced fibrosis remain an at-risk population (Singal 2023, PMID 37884736).

HCV: cure changes, but does not erase, risk

Direct-acting antivirals make sustained virologic response achievable for most treated patients. In a meta-analysis of 23 studies and 29,395 patients, HCC occurrence was 1.54 per 100 person-years after sustained response versus 7.80 among nonresponders (Lv 2024, PMID 38965190). Within the sustained-response population, occurrence was 2.47 per 100 person-years with cirrhosis and 0.85 without cirrhosis; regimen type was not independently associated with higher risk (Lv 2024, PMID 38965190).

These estimates support two simultaneous conclusions:

  • viral cure is primary and secondary cancer prevention;
  • cirrhosis remains a durable risk state after cure and generally remains within surveillance programmes.

Apparent early concerns that direct-acting antivirals uniquely increased HCC risk have not been supported by later comparative meta-analysis, but study populations differ in fibrosis, prior HCC, follow-up, and competing death (Lv 2024, PMID 38965190).

Alcohol-associated HCC

Alcohol was associated with approximately one-fifth of global HCC deaths in 2019, and annual HCC incidence among patients with alcohol-associated cirrhosis ranged from 0.9% to 5.6% across studies (Huang 2023, PMID 36258033). The wide range is informative: age, sex, diabetes, obesity, ongoing alcohol exposure, genetics, ascertainment, and competing decompensation all alter observed incidence.

Alcohol-burden measure Estimate Source population
Alcohol per-capita consumption 5.5 L in 2005; 6.4 L in 2016; projected 7.6 L in 2030 Global modeled data summarized by Huang 2023, PMID 36258033
Share of global cirrhosis deaths associated with alcohol ~25% in 2019 Global estimates (Huang 2023, PMID 36258033)
Share of global HCC deaths associated with alcohol ~20% in 2019 Global estimates (Huang 2023, PMID 36258033)
HCC incidence in alcohol-associated cirrhosis 0.9%–5.6% per year Range across cohorts (Huang 2023, PMID 36258033)

The alcohol and metabolic categories should not be treated as mutually exclusive. Obesity and diabetes are reported modifiers of alcohol-associated cirrhosis and HCC risk, making joint-exposure prevention a priority (Huang 2023, PMID 36258033).

MASLD/MASH: denominator versus individual risk

Approximately one quarter of the world population was estimated to have NAFLD under the prior nomenclature, creating an unusually large at-risk denominator (Huang 2021, PMID 33349658). Yet risk is highly concentrated by fibrosis stage:

Population Estimated HCC incidence Surveillance implication
MASH/NASH cirrhosis 0.5%–2.6% per year Within conventional cirrhosis surveillance populations (Huang 2021, PMID 33349658)
Non-cirrhotic NAFLD/MASLD ~0.1–1.3 per 1,000 patient-years Too low for blanket surveillance; requires enrichment (Huang 2021, PMID 33349658)

This creates a prevention paradox: most individuals with MASLD have low annual HCC risk, but the population is so large that MASLD can contribute a growing number of cases. Some HCC arises before cirrhosis is diagnosed, so a cirrhosis-only surveillance policy will inevitably miss part of the burden (Huang 2021, PMID 33349658). The scientific problem is to identify a small high-risk subgroup without exposing millions of low-risk people to repeated false positives and cost.

See MASH/MASLD and HCC for fibrosis, non-cirrhotic disease, biology, and surveillance implications.

Disparities are part of epidemiology

US evidence demonstrates that incidence is not equivalent to access or outcome. A systematic review and meta-analysis of 35 studies including 563,097 patients found worse survival for Black than White patients (pooled HR 1.08, 95% CI 1.05–1.12) and lower odds of early-stage detection (OR 0.66, 95% CI 0.54–0.78) (Rich 2022, PMID 33387668).

In SEER-Medicare data, only 18.9% of 13,874 older patients received curative treatment; Black patients had lower odds than White patients (OR 0.76, 95% CI 0.64–0.91), with the disparity most pronounced in high-poverty neighbourhoods (Wagle 2022, PMID 34796703). A separate SEER analysis of 45,789 HCC cases found higher incidence, later stage, and poorer survival across many low-socioeconomic-status groups; low-SES Black men had the lowest five-year survival (Flores 2021, PMID 33737301).

These are observational associations, not biological racial effects. Residual confounding by liver function, insurance, geography, referral pathways, transplant access, and treatment eligibility is substantial (Rich 2022, PMID 33387668).

Prevention map

Level Intervention Evidence status Main implementation constraint
Primordial Safer food systems, lower harmful alcohol exposure, obesity/diabetes prevention Strong etiologic rationale; heterogeneous intervention evidence Requires policy beyond hepatology (McGlynn 2021, PMID 32319693)
Primary Universal HBV vaccination and prevention of perinatal transmission Population cancer reduction demonstrated Coverage, timely birth dose, maternal screening (Chang 2009, PMID 19759364)
Primary HCV testing and curative treatment Large reduction in HCC occurrence after sustained response Diagnosis, treatment access, reinfection (Lv 2024, PMID 38965190)
Primary/secondary HBV viral suppression Reduces disease progression; exact causal HCC effect difficult to isolate in older designs Lifelong therapy, residual cirrhotic risk (Thiele 2013, PMID 23945731)
Secondary Six-month surveillance in sufficiently high-risk populations Earlier detection association; mortality evidence debated Underuse and low ultrasound sensitivity (Singal 2023, PMID 37884736)
Tertiary Antiviral and liver-disease control after curative HCC treatment Etiology-specific recurrence prevention Tumor biology and field carcinogenesis persist

Putative chemopreventive associations involving aspirin, statins, metformin, or coffee remain non-causal and are not a substitute for etiologic control (Singal 2023, PMID 37884736).

Interpretation limits

  • GLOBOCAN estimates are modeled and largely refer to liver cancer, not HCC alone (Bray 2024, PMID 38572751).
  • Etiologic attribution changes as diagnostic coding and alcohol/metabolic definitions change.
  • Falling viral-attributable fractions can coexist with rising absolute case counts as populations age.
  • HCC incidence after viral cure is strongly confounded by fibrosis stage and prior HCC.
  • Race and ethnicity are social and structural variables in these analyses, not mechanistic tumor categories.
  • The MASLD nomenclature change creates discontinuity with the NAFLD-based historical evidence base.

Quantified risk architecture

The etiologic labels overlap rather than partitioning patients cleanly. A 2026 meta-analysis of 857 publications estimated global HCC attributable fractions of 52% for HBV and 21% for HCV, corresponding to approximately 345,434 and 134,418 cases in 2022; HBV attribution ranged from 70% in Eastern Asia to 6% in Northern Europe, while HCV attribution reached 77% in Northern Africa (Cao 2026, PMID 42135055). HDV is a smaller but highly concentrated multiplier: among HBsAg-positive people, pooled anti-HDV prevalence was 4.5% (95% CI 3.6–5.7), and preliminary population-attributable fractions were 18% for cirrhosis and 20% for HCC (Stockdale 2020, PMID 32335166).

Exposure or system factor Quantified association Interpretation and boundary
HBV infection 12.5-fold HCC risk in an umbrella review Strong causal evidence, but magnitude pools heterogeneous populations and viral states (Wang 2025, PMID 39834076)
HCV infection 11.2-fold HCC risk in the same umbrella review Cure reduces but does not erase risk once advanced fibrosis is established (Wang 2025, PMID 39834076)
Diabetes in chronic HBV Fixed-effect HR 1.26 (95% CI 1.20–1.32); random-effects HR 1.36 (1.23–1.49) Metformin adjustment attenuated the estimate, illustrating treatment/confounding entanglement (Campbell 2021, PMID 33305479)
Diabetes, all etiologies Case-control OR 2.5 (95% CI 1.8–3.5); cohort RR 2.5 (1.9–3.2) Older evidence; incomplete control for obesity and diet limits causal attribution (El-Serag 2006, PMID 16527702)
Aflatoxin Population-attributable risk 17% (14–19%) overall; 21% in HBV-positive and 8.8% in HBV-negative populations Evidence came from China, Taiwan, and sub-Saharan Africa; exposure reduction and HBV control are complementary (Liu 2012, PMID 22405700)
Aflatoxin plus HBV OR 73.0 (95% CI 36.0–148.3), versus 11.3 for HBV alone and 6.37 for aflatoxin alone after excluding one heterogeneous study Supports multiplicative interaction, not simple addition (Liu 2012, PMID 22405700)
Two additional cups of coffee/day RR 0.65 (95% CI 0.59–0.72); cohort-only RR 0.71 (0.65–0.77) Observational association; GRADE certainty was very low and does not establish a prescription (Kennedy 2017, PMID 28490552)
NAFLD global prevalence 25.24% (95% CI 22.10–28.65) in meta-analysis A large exposed denominator makes even low individual non-cirrhotic incidence consequential (Younossi 2016, PMID 26707365)
Low educational attainment Illiteracy OR 1.37 (95% CI 1.00–1.89); ≥12 years education OR 0.37 (0.23–0.59) Socioeconomic indicators are contextual exposures, not biological traits (Lu 2022, PMID 35252078)
Treatment delay 14.3% delayed >3 months; delay HR for mortality 1.15 (95% CI 1.05–1.25) Black race and high-poverty residence had higher odds of delay, identifying a modifiable care-process pathway (Wagle 2023, PMID 35933076)

Etiology is also a health-system phenotype

In a four-system US cohort, only 42.0% presented at BCLC 0/A. The adjusted odds of early presentation were lower for Black than White patients (OR 0.63, 95% CI 0.45–0.89); an initially higher Black–White mortality hazard (HR 1.30, 95% CI 1.09–1.53) disappeared after adding stage and treatment (HR 1.05, 95% CI 0.88–1.24), implicating access and treatment pathways rather than race as innate biology (Rich 2024, PMID 39666898). Environmental and socioeconomic meta-analysis likewise found heterogeneous associations across education, income, rural residence, occupation, pesticide exposure, and aflatoxin, with wide intervals for several estimates; these should be treated as linked structural exposures rather than a checklist of independent causes (Lu 2022, PMID 35252078).

Prevention controversies

  • Causal prevention versus association. HBV vaccination, HBV suppression, and HCV cure act on established causes; coffee, statins, metformin, aspirin, and GLP-1 receptor agonists remain largely supported by observational syntheses vulnerable to healthy-user, indication, and immortal-time biases (Wang 2025, PMID 39834076).
  • Residual risk after viral control. The falling viral fraction does not mean viral HCC has disappeared: the absolute burden remains large, and cirrhosis, age, diabetes, alcohol, and persistent viral markers continue to stratify risk after treatment (Cao 2026, PMID 42135055; Campbell 2021, PMID 33305479).
  • Metabolic attribution. MASLD, diabetes, and obesity are correlated and frequently coexist with alcohol or viral hepatitis; assigning a single etiology can obscure joint causation and distort trend estimates (Xiao 2024, PMID 39047929).
  • Geographic transportability. Aflatoxin-HBV synergy is compelling in high-exposure regions, but its attributable fraction cannot be transported unchanged to food systems with low contamination (Liu 2012, PMID 22405700).

Open questions

  • Which combined viral, alcohol, metabolic, genetic, and fibrosis models transport across regions well enough to allocate prevention resources (Singal 2023, PMID 37884736)?
  • What population intervention can reduce alcohol-associated HCC with an effect comparable to HBV vaccination (Huang 2023, PMID 36258033)?
  • How should post-HCV-cure surveillance be discontinued, if ever, in patients whose fibrosis regresses (Lv 2024, PMID 38965190)?
  • Can a sufficiently small, high-risk non-cirrhotic MASLD subgroup be identified for cost-effective surveillance (Huang 2021, PMID 33349658)?
  • Which structural intervention most efficiently closes the early-detection and curative-treatment gaps affecting low-SES and Black US populations (Rich 2022, PMID 33387668; Wagle 2022, PMID 34796703)?

References

  1. Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229-263. PMID 38572751
  2. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology. 2021;73 Suppl 1:4-13. PMID 32319693
  3. Singal AG, Kanwal F, Llovet JM. Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy. Nat Rev Clin Oncol. 2023;20:864-884. PMID 37884736
  4. Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol. 2020;18:2650-2666. PMID 31401364
  5. Yang JD, et al. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16:589-604. PMID 31439937
  6. Chang MH, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101:1348-1355. PMID 19759364
  7. Thiele M, et al. Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis. BMJ Open. 2013;3:e003265. PMID 23945731
  8. Lv GJ, et al. Risk of hepatocellular carcinoma occurrence after antiviral therapy for patients with chronic hepatitis C infection: a systematic review and meta-analysis. Hepatol Int. 2024;18:1459-1471. PMID 38965190
  9. Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2021;18:223-238. PMID 33349658
  10. Huang DQ, et al. Global epidemiology of alcohol-associated cirrhosis and HCC: trends, projections and risk factors. Nat Rev Gastroenterol Hepatol. 2023;20:37-49. PMID 36258033
  11. Rich NE, et al. Racial and ethnic disparities in survival among patients with hepatocellular carcinoma in the United States: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20:2019-2030. PMID 33387668
  12. Wagle NS, et al. Racial, ethnic, and socioeconomic disparities in curative treatment receipt and survival in hepatocellular carcinoma. Hepatol Commun. 2022;6:1186-1197. PMID 34796703
  13. Flores YN, et al. Disparities in hepatocellular carcinoma incidence, stage, and survival: a large population-based study. Cancer Epidemiol Biomarkers Prev. 2021;30:1193-1199. PMID 33737301
  14. Cao M, et al. Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis. Gut. 2026. PMID 42135055
  15. Liu Y, et al. Population attributable risk of aflatoxin-related liver cancer: systematic review and meta-analysis. Eur J Cancer. 2012;48:2125-2136. PMID 22405700
  16. Kennedy OJ, et al. Coffee, including caffeinated and decaffeinated coffee, and the risk of hepatocellular carcinoma: a systematic review and dose-response meta-analysis. BMJ Open. 2017;7:e013739. PMID 28490552
  17. Wang J, et al. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis. Ann Med. 2025;57:2455539. PMID 39834076
  18. Campbell C, et al. Risk factors for the development of hepatocellular carcinoma in chronic HBV infection: a systematic review and meta-analysis. J Viral Hepat. 2021;28:493-507. PMID 33305479
  19. El-Serag HB, et al. The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol. 2006;4:369-380. PMID 16527702
  20. Lu W, et al. Association between environmental and socioeconomic risk factors and hepatocellular carcinoma: a meta-analysis. Front Public Health. 2022;10:741490. PMID 35252078
  21. Wagle NS, et al. Racial, ethnic, and socioeconomic disparities in treatment delay among patients with hepatocellular carcinoma in the United States. Clin Gastroenterol Hepatol. 2023;21:1281-1292.e10. PMID 35933076
  22. Rich NE, et al. Impact of racial, ethnic, and socioeconomic disparities on presentation and survival of HCC: a multicenter study. Hepatol Commun. 2024;8. PMID 39666898
  23. Stockdale AJ, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523-532. PMID 32335166
  24. Younossi ZM, et al. Global epidemiology of nonalcoholic fatty liver disease: meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73-84. PMID 26707365
  25. Xiao S, et al. Modifiable risk factors for hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease: a meta-analysis. Am J Med. 2024;137:1072-1081.e32. PMID 39047929